SWOG clinical trial number
SWOG-9149
A Phase II Study of Cisplatin Preceded by a 12-Hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside (Ara-C) for Adult Patients with Malignant Gliomas
Closed
Phase
Accrual
89%
Published
Research committees
Brain Cancer
Treatment
Hydroxyurea
Cytosine Arabinoside
Cisplatin
Eligibility Criteria Expand/Collapse
¤8??aD¤ically confirmed diagnosis of glioblastoma or astrocytoma (Grade III-IV); biopsy slides must be available for path. review; tumor must be either recurrent, progressive or persistent disease as documented by CT or MRI; patients must have bidimensionally measurable disease; patients must have received adequate radiation therapy; prior surgery is allowed; prior chemo allowed.
Publication Information Expand/Collapse
2008
A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149) [PMID18175205]
2004
A phase II study of cisplatin preceded by a 12-hour continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas